2024-01-19 15:42:00
A 67-year-old woman died following suffering a severe allergic reaction to the drug adagrasib, which is prescribed to patients with non-small cell lung cancer. Only patients undergoing this treatment are allowed to take it in France.
On January 9, the National Medicines Safety Agency published a press release dedicated to health professionals. Its purpose was to report the risk of severe skin side effects of adagrasib following a patient death.
Epidermal necrolysis
Epidermal necrolysis is a rare, life-threatening skin reaction, usually caused by a drug. Although it is very rare (its incidence ranges between 2 and 6 cases per year per million people), its seriousness served as a warning to the responsible authorities. The Medicines Agency has temporarily halted the start of new treatment with adagrasib as part of the Access Program.
Although it is extremely rare, its seriousness has alerted responsible authorities, according to what was published on the website Topsante.
The National Agency for Drug Safety revealed a group of warning symptoms for people taking this drug. Signs of allergy can be mild and appear in the form of conjunctivitis or pharyngitis. So if you suspect any symptom, do not hesitate to consult a dermatologist.
The symptoms that require emergency consultation are:
* Widespread skin pain.
* A skin rash that spreads quickly
* Large patches of skin peel
* Ulceration, swelling, and peeling of the mucous membranes, including the membranes of the mouth, eyes, and vagina.
Returning to the drug, it has been approved in the American market for patients with non-small cell lung cancer. In the European market, the situation is different. It has been licensed by the European Committee for Medicinal Products for Human Use since November 9, 2023, while the European Commission’s decision is still pending. There is no doubt that the woman’s death will have an impact and weight on decision-making.
1705822527
#medicine #death #Epidermal #necrolysis #killed #patient
